<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974779</url>
  </required_header>
  <id_info>
    <org_study_id>KIM2H-2009-02</org_study_id>
    <nct_id>NCT00974779</nct_id>
  </id_info>
  <brief_title>High-cutoff Hemodialyzer to Reduce Chronic Inflammation in Hemodialysis Patients</brief_title>
  <acronym>HCO1100</acronym>
  <official_title>Application of the &quot;High-cutoff (HCO1100)&quot; Hemodialyzer to Reduce Chronic Inflammation in Hemodialysis Patients With Elevated CRP Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universit채t Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gambro Dialysatoren GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>KfH Kuratorium f체r Dialyse und Nierentransplantation e.V., Neu Isenburg, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universit채t Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether a dialyzer with a higher than usual permeability
      for proteins can eliminate proinflammatory proteins from the blood of patients on regular
      maintenance hemodialysis who have chronically elevated levels of inflammation markers such as
      C-reactive protein (CRP) in their blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with ESRD on chronic hemodialysis patients frequently have elevated markers of
      inflammation (e.g. serum CRP values). Hemodialysis may clear the blood from low molecular
      weight toxins and retention products such as creatinine, potassium, or urea. The dialyzer
      clearance of middle to high molecular weight substances such as cytokines and cytokine
      receptors is low. Nearly 50% of chronic dialysis patients have persistent subclinical
      inflammation which is strongly associated with cardiovascular disease and mortality. The
      study tests the hypothesis that removal of proteins in the weight range of 10.000-30.000 D
      via a more permeable dialyzer membrane reduces chronic inflammation in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammation: CRP plasma level and quantity of circulating CD14/16 positive monocytes</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum albumin losses</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>HCO dialyzer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis with the HCO1100 hemodialyzer membrane with high molecular weight cut off.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular dialysis using a polyamide high-flux hemodialyzer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HCO1100 dialyzer</intervention_name>
    <description>Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks</description>
    <arm_group_label>HCO dialyzer</arm_group_label>
    <other_name>Gambro HCO1100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>regular dialysis polyamide</intervention_name>
    <description>Continuation of the regular hemodialysis using polyamide high-flux hemodialysers</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Gambro Polyflux 11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  regular hemodialysis for at least 3 months

          -  treatment thrice weekly

          -  high-flux hemodialyzer for at least 4 weeks

          -  age &gt; 18 years and &lt; 80 years

          -  at least one CRP value &gt; 5mg/L within 8 weeks before inclusion

          -  able to understand and consent the study

          -  written informed consent

        Exclusion Criteria:

          -  no consent

          -  clinically apparent acute infection

          -  CRP &gt; 50 mg/L

          -  serum albumin &lt; 3,5 mg/L

          -  central venous line as dialysis access

          -  immunosuppressive medication

          -  pregnancy or lactation

          -  inclusion into any other interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Internal Medicine II, Martin-Luther-University Medical School</name>
      <address>
        <city>Halle (Saale)</city>
        <state>Sachsen-Anhalt</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <last_update_submitted>January 13, 2012</last_update_submitted>
  <last_update_submitted_qc>January 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universit채t Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Matthias Girndt</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>kidney failure chronic</keyword>
  <keyword>renal dialysis</keyword>
  <keyword>inflammation</keyword>
  <keyword>monocytes</keyword>
  <keyword>end stage renal disease on regular thrice weekly hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

